Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 12/2019

01-12-2019 | Andropause | Letter to the Editor

Drug holidays in osteoporosis treatment: mind the gaps!

Authors: P. Anagnostis, I. Lambrinoudaki, E. Kenanidis, M. Potoupnis, E. Tsiridis, D.G. Goulis

Published in: Osteoporosis International | Issue 12/2019

Login to get access

Excerpt

Nayak et al. in their recent study [1] performed a meta-analysis of the literature regarding the effect of bisphosphonate discontinuation (“drug holiday”) on bone mineral density (BMD) and fracture risk. …
Literature
1.
2.
Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Pérez-López FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Trémollieres FA, Goulis DG (2017) Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas 101:23–30CrossRef
3.
Black D, Schwartz A, Ensrud K et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 296:2927–2938CrossRef
4.
Bone H, Hosking D, Devogelaer J et al (2004) Alendronate phase III osteoporosis treatment study group (2004) ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199CrossRef
5.
Black D, Reid I, Boonen S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res 27:243–254CrossRef
6.
Black D, Reid I, Cauley J et al (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res 30:934–944CrossRef
7.
Schilcher J, Koeppen V, Aspenberg P, Michaelsson K (2014) Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med 371:974–976CrossRef
Metadata
Title
Drug holidays in osteoporosis treatment: mind the gaps!
Authors
P. Anagnostis
I. Lambrinoudaki
E. Kenanidis
M. Potoupnis
E. Tsiridis
D.G. Goulis
Publication date
01-12-2019
Publisher
Springer London
Published in
Osteoporosis International / Issue 12/2019
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-019-05027-1

Other articles of this Issue 12/2019

Osteoporosis International 12/2019 Go to the issue

Review

Fracture-induced changes in biomarkers CTX, PINP, OC, and BAP—a systematic review

Review

Percutaneous vertebroplasty versus non-operative treatment for osteoporotic vertebral compression fractures: a meta-analysis of randomized controlled trials

Letter to the Editor

Calcifediol or vitamin D to optimize vitamin D status: Reply to letter of M Sosas

Original Article

A bone resorption marker as predictor of rate of change in femoral neck size and strength during the menopause transition

Editorial

Bisphosphonates and lower mortality risk: when it sounds to be good to be true …

Original Article

The association between sarcopenia and osteoporotic vertebral compression refractures